Tara Bancroft, an analyst from TD Cowen, maintained the Buy rating on TG Therapeutics. The associated price target remains the same with $50.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Tara Bancroft’s rating is based on several key factors that highlight the positive trajectory of TG Therapeutics. The company reported $139 million in net U.S. revenue for Briumvi in the second quarter, which, although slightly below some investor expectations, exceeded the company’s guidance by approximately $4 million. This consistent outperformance of guidance, combined with a conservative yet optimistic revenue forecast for the year, underscores the company’s strong market position.
TG Therapeutics has also seen significant growth in new patient enrollments and prescriber accounts, indicating a robust market penetration for Briumvi. The drug’s expanding availability in international markets such as the EU, UK, Switzerland, and Australia is expected to enhance royalty revenues in the future. Additionally, the lack of competitive pressure from other treatments and the increase in repeat prescriptions further support the company’s growth prospects, making the stock an attractive buy according to Tara Bancroft.